Literature Review
Literature Review
MRI is a poor disability predictor in secondary progressive MS
Literature Review
Progressive disability in MS explained?
Complete resolution of brain lesions may help distinguish MS, MOGAD, and AQP4+ NMOSD.
Literature Review
Neurologic drug prices jump 50% in five years
Most of the increased cost was due to rising costs for neuroimmunology drugs, mainly for those used to treat multiple sclerosis (MS).
Literature Review
MS bears no effect on certain pregnancy complications, stillbirth, or congenital deformation
Women with MS were more likely to have elective C-sections, induced labor, and babies with low birth weight based on their gestational age.
Literature Review
Is the EDSS an adequate outcome measure in secondary progressive MS trials?
Investigators say it may be time to replace as a primary outcome measure an instrument that registers more improvement than is likely possible in...
Literature Review
Stem cell transplant shows long-term benefit in MS
“Autologous hematopoietic stem cell transplant should be considered as a treatment strategy for MS not responding to conventional therapy.”
Literature Review
Which imaging criteria identify progressive forms of MS?
Identification of imaging features associated with primary progressive MS and features that predict evolution from relapsing-remitting MS to...
Literature Review
In MS, serious adverse effects are more common in rituximab versus ocrelizumab
Infection rates are high among reported AEs, and related deaths weren’t uncommon, researchers reported.
Literature Review
Lowering rituximab dose in patients with MS proves safe and effective
Among study participants, no relapses occurred in the year after lowering rituximab dosage to 500 mg.
Literature Review
Relapsing, progressive MS classifications should be abandoned
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”